Update on rational targeted therapy in AML.

[1]  S. Grant,et al.  Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation , 2015, Haematologica.

[2]  G. Rosner,et al.  Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia , 2015, Haematologica.

[3]  M. Weiss,et al.  Immunotherapy in acute myeloid leukemia , 2015, Cancer.

[4]  Scott A Armstrong,et al.  Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. , 2015, Experimental hematology.

[5]  M. Grunwald,et al.  FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia. , 2015, Seminars in hematology.

[6]  L. Marchionni,et al.  Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia , 2015, Science Translational Medicine.

[7]  H. Dombret,et al.  BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells , 2015, Oncotarget.

[8]  M. Maris,et al.  Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study , 2015, British journal of haematology.

[9]  S. Grant,et al.  Rational Combinations of Targeted Agents in AML , 2015, Journal of clinical medicine.

[10]  W. Sellers,et al.  Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure , 2015, EMBO reports.

[11]  J. Issa,et al.  Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia , 2015, Cancer.

[12]  J. Chi,et al.  Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol , 2015, Haematologica.

[13]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[14]  M. Levis,et al.  Targeting FLT3 to treat leukemia , 2015, Expert opinion on therapeutic targets.

[15]  Manish R. Patel,et al.  AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies , 2014 .

[16]  S. Armstrong,et al.  The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia , 2014 .

[17]  M. Maris,et al.  Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial , 2014 .

[18]  G. Garcia-Manero,et al.  Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML) , 2014 .

[19]  Traci M. Blonquist,et al.  A Phase I Study of the Aurora a Kinase Inhibitor Alisertib in Combination with 7+3 Induction Chemotherapy in Patients with Acute Myeloid Leukemia , 2014 .

[20]  A. Letai,et al.  A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) , 2014 .

[21]  H. Dombret,et al.  A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia , 2014 .

[22]  W. Pierceall,et al.  Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts) , 2014 .

[23]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[24]  Hua Yang,et al.  1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies , 2014 .

[25]  S. Grant,et al.  A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations , 2014, Leukemia.

[26]  M. Tallman,et al.  A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia , 2014, PloS one.

[27]  J. Issa,et al.  A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome , 2014, British journal of haematology.

[28]  S. Grant,et al.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. , 2014, Pharmacology & therapeutics.

[29]  K. Döhner,et al.  Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. , 2014, Blood.

[30]  Daniel Paech,et al.  Nuclear Overhauser Enhancement Mediated Chemical Exchange Saturation Transfer Imaging at 7 Tesla in Glioblastoma Patients , 2014, PloS one.

[31]  E. Estey,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.

[32]  J. Qi,et al.  BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD , 2014, Molecular Cancer Therapeutics.

[33]  P. Westervelt,et al.  An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes , 2014, Leukemia research reports.

[34]  J. Cortes,et al.  Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. , 2014, Blood.

[35]  J. Herman,et al.  Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Qi,et al.  Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells , 2014, Molecular Cancer Therapeutics.

[37]  R. D'Andrea,et al.  Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome , 2014, Blood Cancer Journal.

[38]  Stefan Fröhling,et al.  Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. , 2013, Blood.

[39]  H. Dombret,et al.  Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias , 2013 .

[40]  M. Konopleva,et al.  A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS , 2013 .

[41]  T. Naoe,et al.  Treatment With Hedgehog Inhibitor, PF-04449913, Attenuates Leukemia-Initiation Potential In Acute Myeloid Leukemia Cells , 2013 .

[42]  C. Korch,et al.  Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality , 2013, Molecular Cancer Therapeutics.

[43]  J. Aurelius,et al.  Immunotherapeutic strategies for relapse control in acute myeloid leukemia. , 2013, Blood reviews.

[44]  H. Kantarjian,et al.  Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia , 2013, Cancer.

[45]  T. Yamauchi,et al.  Aurora B inhibitor barasertib and cytarabine exert a greater‐than‐additive cytotoxicity in acute myeloid leukemia cells , 2013, Cancer science.

[46]  R. Larson,et al.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.

[47]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[48]  O. Abdel-Wahab,et al.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. , 2013, Blood.

[49]  John D. Roberts,et al.  A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 , 2013, Clinical Cancer Research.

[50]  S. Grant,et al.  Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. , 2013, Cancer research.

[51]  M. Konopleva,et al.  Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms , 2012 .

[52]  S. Sugano,et al.  Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. , 2012, Blood.

[53]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Kohlmann,et al.  Landscape of TET2 mutations in acute myeloid leukemia , 2012, Leukemia.

[55]  D. Gao,et al.  Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and novel therapeutic target in acute myeloid leukemia , 2011, Leukemia.

[56]  T. Somervaille,et al.  Pharmacological Inhibition or Genetic Knockdown of Kdm1a (Lsd1 or Aof2) Induces Differentiation of MLL Acute Myeloid Leukaemia Stem Cells , 2011 .

[57]  J. Chandra,et al.  HDAC and LSD1 Inhibitors Synergize to Induce Cell Death in Acute Leukemia Cells , 2011 .

[58]  C. Croce,et al.  Mir-155 Contributed to Chronic Lymphocytic Leukemia Survival by Modulation of BCR-Signalling , 2011 .

[59]  B. Djulbegovic,et al.  Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on Quality of Treatment Related Harms Reporting: An Analysis of National Cancer Institute's Co-Operative Group Phase III Randomized Controlled Trials , 2011 .

[60]  Yow-Ming C Wang,et al.  A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. , 2011, Blood.

[61]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[62]  Robert H. Kuss,et al.  Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. , 2011, Leukemia research.

[63]  J. Licht,et al.  DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.

[64]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[65]  R. Schlenk,et al.  Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine , 2010 .

[66]  G. Wilding,et al.  Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies , 2010 .

[67]  D. Porter,et al.  Effect of Pharmacokinetic Variability on the Toxicity and Efficacy of High-Dose Melphalan for Multiple Myeloma , 2010 .

[68]  G. Morgan,et al.  Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Ouillette,et al.  Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.

[70]  M. McDevitt,et al.  Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. , 2010, Leukemia research.

[71]  Francis J Giles,et al.  Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. , 2010, Blood.

[72]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Sabrina Smith,et al.  The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine. , 2009 .

[74]  L. Bullinger,et al.  Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG). , 2009 .

[75]  Christian Bailly,et al.  Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. , 2009, Blood.

[76]  R. Takimoto,et al.  Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells , 2009, Cancer science.

[77]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[78]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[79]  B. Cheson,et al.  A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.

[80]  N. Curtin,et al.  Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked , 2008, Cell cycle.

[81]  C. Sawyers,et al.  Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors , 2008 .

[82]  N. Russell,et al.  The Effect of ABC Transporters and FLT3 Status on the Activity of the Aurora Kinase B Inhibitor AZD1152 in AML Cells. , 2008 .

[83]  M. Konopleva,et al.  Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. , 2008, Blood.

[84]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Interaction for Cancer Therapy , 2008, Clinical Cancer Research.

[85]  S. Fesik,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[86]  Jorge A. Almenara,et al.  Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions , 2007, Molecular Cancer Therapeutics.

[87]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[88]  M. Grever,et al.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.

[89]  Peter M Fischer,et al.  Recent progress in the discovery and development of cyclin-dependent kinase inhibitors , 2005, Expert opinion on investigational drugs.

[90]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[91]  Jorge A. Almenara,et al.  The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. , 2002, Molecular cancer therapeutics.

[92]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  H. Kantarjian,et al.  Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukeaemia (OPAL): a randomized open-label phase 2 study , 2017 .

[94]  G. Schiller,et al.  Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials. , 2015, Blood reviews.

[95]  F. Kim,et al.  The Cancer , 2015, International braz j urol : official journal of the Brazilian Society of Urology.

[96]  V. Markovtsov,et al.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen , 2009, Journal of Cancer Research and Clinical Oncology.

[97]  J. Karp,et al.  Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.